Benefits of eprenetapopt plus azacytidine for TP53-mutant MDS and oligoblastic AML
The combination therapy of eprenetapopt plus azacytidine showed favorable efficacy and safety in patients with TP53-mutant myelodysplastic syndrome (MDS) and oligoblastic acute myeloid leukemia (AML). Patients with biallelic...
Read More